Clinical trials: Cocaine Use Disorders
Cocaine Use Disorder
Exenatide for Treating Cocaine Use Disorder
The purpose of this study is to collect information about whether exenatide (Bydureon) may be safe and helpful as a medication treatment for individuals who want to stop using cocaine.
- Trial name
- NCT04941521
- Testing
- Exenatide 2 mg [Bydureon], Drug Counseling
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Stimulant Use & Co-occuring Opioid Use Disorders
Stimulant Oxytocin Study
This study will investigate the effects of intranasal administration of oxytocin, a social neuropeptide, on reducing stimulant use, enhancing therapeutic engagement, and susceptibility to stress-induced relapse in Veterans with…
- Trial name
- SOS (NCT03016598)
- Testing
- Intranasal oxytocin
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- VA Office of Research and Development
Cocaine Dependence, Methamphetamine Dependence
Smoking-Cessation and Stimulant Treatment (S-CAST)
The primary objective of this study is to evaluate the impact of substance-abuse treatment as usual plus smoking-cessation treatment (TAU+SCT), relative to substance-abuse treatment as usual (TAU), on drug-abuse outcomes.
- Conditions
- Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
- Trial name
- S-CAST (NCT01077024)
- Testing
- Smoking-cessation treatment
- Where
- 12 sites in United States
- Volunteers
- 538 people
- Sponsor
- University of Cincinnati
Drug Abuse
Stimulant Abuser Groups to Engage in 12-Step
The purpose of this study is to determine whether a combined group and individual 12-Step facilitative (TSF) intervention, Stimulant Abuser Groups to Engage in 12 -Step (STAGE-12), improves substance -related outcomes.
- Trial name
- STAGE-12 (NCT00573183)
- Testing
- STAGE-12, Treatment as Usual
- Where
- 10 sites in United States
- Volunteers
- 471 people
- Sponsor
- University of Washington
Schizophrenia, Schizoaffective Disorder
Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
The proposed study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Substance Use Disorders
- Trial name
- NCT03526354
- Testing
- Brexpiprazole, Treatment as Usual
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Massachusetts, Worcester
Cocaine Use Disorder
Identifying Electrophysiological Targets for Transcranial Magnetic Stimulation in Cocaine Use Disorder (Pilot Study)
The purpose of this study is to assess the effects of active intermittent theta burst stimulation (iTBS) to dorsomedial prefrontal cortex (dmPFC) on electroencephalogram (EEG) measures of reward sensitivity and cue reactivity and…
- Trial name
- NCT05631548
- Testing
- iTBS to dmPFC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cocaine Use Disorders
D-Cycloserine and Cue Exposure in Cocaine-Dependent Individuals
In summary, this pilot study will explore the use of an innovative pharmacologic approach to the treatment of substance dependence through the facilitation of extinction of response to cocaine-conditioned cues in…
- Trial name
- NCT00780442
- Testing
- D-cycloserine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Medical University of South Carolina
Cocaine-Related Disorders
Lorcaserin in the Treatment of Cocaine Use Disorder
The objective of this study is to evaluate the efficacy and safety of lorcaserin in the treatment of cocaine use disorder.
- Trial name
- NCT03007394
- Testing
- Lorcaserin
- Where
- 12 sites in United States
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Cocaine Use Disorder
Suvorexant and Cocaine
The research proposed here will translate findings from preclinical research and provide the initial clinical evidence that orexin antagonism reduces motivation for cocaine, as well as other cocaine-associated maladaptive…
- Trial name
- NCT03937986
- Testing
- Suvorexant, Cocaine
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- William Stoops
Cocaine Dependence
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
The purpose of this study is to examine the effects of the administration of Risperidal-Consta on the brain's reward circuitry using Magnetic resonance Imaging (MRI), behavioral tests and measuring cocaine craving and use among…
- Trial name
- NCT00385801
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Cocaine-Related Disorders, Anhedonia
Targeting Anhedonia in Cocaine Use Disorder
The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD).
- Trial name
- NCT02773212
- Testing
- d-amphetamine, Contingency management
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Illinois Chicago
Cocaine Use Disorder
Neurobehavioral Mechanisms of Cocaine Choice
The objective of this protocol is to use a drug-vs-money choice task, reinforcement learning modeling and fMRI to determine the neurobehavioral and neurobiological decision-making "profile" associated with the decision to take…
- Trial name
- NCT04296006
- Testing
- Money, Cocaine HCl
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Joshua A. Lile, Ph.D.
Cocaine-related Disorder
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
This study assessed whether AFQ056 had a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
- Trial name
- NCT03242928
- Testing
- AFQ056
- Where
- 8 sites in Argentina, Spain and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals